Because of these characteristics, liposomal iron is a therapeutic option to correct iron deficiency, particularly indicated for NDD-CKD patients, as it can potentially overcome the adverse effects on iron metabolism induced by an eventual increase in hepcidin levels with consequent lower expression of ferroportin on the basal membrane of enterocytes [3,11]. Here, SLC40A1 is linked to chronic kidney disease.